{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:46:04Z","timestamp":1789951564834,"version":"4.0.1"},"reference-count":48,"publisher":"Portland Press Ltd.","issue":"13","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,18]]},"abstract":"<jats:p>Highly viscous mucus and its impaired clearance characterize the lungs of patients with cystic fibrosis (CF). Pulmonary secretions of patients with CF display increased concentrations of high molecular weight components such as DNA and actin. Recombinant human deoxyribonuclease I (rhDNase) delivered by inhalation cleaves DNA filaments contained in respiratory secretions and thins them. However, rapid clearance of rhDNase from the lungs implies a daily administration and thereby a high therapy burden and a reduced patient compliance. A PEGylated version of rhDNase could sustain the presence of the protein within the lungs and reduce its administration frequency. Here, we evaluated the enzymatic activity of rhDNase conjugated to a two-arm 40 kDa polyethylene glycol (PEG40) in CF sputa. Rheology data indicated that both rhDNase and PEG40-rhDNase presented similar mucolytic activity in CF sputa, independently of the purulence of the sputum samples as well as of their DNA, actin and ions contents. The macroscopic appearance of the samples correlated with the DNA content of the sputa: the more purulent the sample, the higher the DNA concentration. Finally, quantification of the enzymes in CF sputa following rheology measurement suggests that PEGylation largely increases the stability of rhDNase in CF respiratory secretions, since 24-fold more PEG40-rhDNase than rhDNase was recovered from the samples. The present results are considered positive and provide support to the continuation of the research on a long acting version of rhDNase to treat CF lung disease.<\/jats:p>","DOI":"10.1042\/cs20180315","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T12:15:31Z","timestamp":1528200931000},"page":"1439-1452","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum"],"prefix":"10.1042","volume":"132","author":[{"given":"Marie-Julie","family":"Guichard","sequence":"first","affiliation":[{"name":"Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute (LDRI), Universit\u00e9 catholique de Louvain, Brussels 1200, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kinoo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, University Hospitals Leuven, Leuven 3000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Aubriot","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Unit, Cliniques Universitaires St Luc, Universit\u00e9 catholique de Louvain, Brussels 1200, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bauwens","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Unit, Cliniques Universitaires St Luc, Universit\u00e9 catholique de Louvain, Brussels 1200, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordane","family":"Gougu\u00e9","sequence":"additional","affiliation":[{"name":"Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute (LDRI), Universit\u00e9 catholique de Louvain, Brussels 1200, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, University Hospitals Leuven, Leuven 3000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lebecque","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Unit, Cliniques Universitaires St Luc, Universit\u00e9 catholique de Louvain, Brussels 1200, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresinha","family":"Leal","sequence":"additional","affiliation":[{"name":"Louvain Center for Toxicology and Applied Pharmacology, Institute of Experimental and Clinical Research (IREC), Universit\u00e9 catholique de Louvain, Brussels 1200, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Vanbever","sequence":"additional","affiliation":[{"name":"Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute (LDRI), Universit\u00e9 catholique de Louvain, Brussels 1200, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"2021113010583852600_B1","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic Fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med. Massachusetts Med. Soc."},{"key":"2021113010583852600_B2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113010583852600_B3","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMra0910061","article-title":"Airway mucus function and dysfunction","volume":"363","author":"Fahy","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2021113010583852600_B4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.addr.2008.09.012","article-title":"Micro- and macrorheology of mucus","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2021113010583852600_B5","first-page":"83","article-title":"Studies on pulmonary secretions. II. Osmolality and the ionic environment of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy","volume":"91","author":"Potter","year":"1967","journal-title":"Am. Rev. Respir. Dis."},{"key":"2021113010583852600_B6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1159\/000363242","article-title":"Cystic fibrosis sputum DNA has NETosis characteristics and neutrophil extracellular trap release is regulated by macrophage migration-inhibitory factor","volume":"6","author":"Dwyer","year":"2014","journal-title":"J. Innate. Immun."},{"key":"2021113010583852600_B7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3109\/10611869608995625","article-title":"Distribution of DNA and alginate in purulent cystic fibrosis sputum: implications to pulmonary targeting strategies","volume":"4","author":"Mrsny","year":"1996","journal-title":"J. Drug Target"},{"key":"2021113010583852600_B8","first-page":"89","volume-title":"Biopolymer Induced Changes in Mucus Viscoelasticity","author":"Marriott","year":"1982"},{"key":"2021113010583852600_B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0009-8981(87)90065-9","article-title":"Relationships between the lipid content and the rheological properties of airway secretions in cystic fibrosis","volume":"164","author":"Galabert","year":"1987","journal-title":"Clin. Chim. Acta"},{"key":"2021113010583852600_B10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/BIR-1984-211-227","article-title":"Cation induced changes in the rheological properties of purified mucus glycoprotein gels","volume":"21","author":"Crowther","year":"1984","journal-title":"Biorheology"},{"key":"2021113010583852600_B11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1196\/annals.1415.006","article-title":"The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4","volume":"1112","author":"Kater","year":"2007","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2021113010583852600_B12","doi-asserted-by":"publisher","first-page":"9188","DOI":"10.1073\/pnas.87.23.9188","article-title":"Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum","volume":"87","author":"Shak","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010583852600_B13","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.1073\/pnas.93.16.8225","article-title":"Engineering actin-resistant human DNase I for treatment of cystic fibrosis","volume":"93","author":"Ulmer","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"2021113010583852600_B14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3109\/9781420044386-20","article-title":"Recombinant human deoxyribonuclease I","author":"Lazarus","year":"2007","journal-title":"Pharm. Biotechnol."},{"key":"2021113010583852600_B15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/106002809603000614","article-title":"The role of dornase alfa in the treatment of cystic fibrosis","volume":"30","author":"Cramer","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"2021113010583852600_B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijpharm.2017.03.057","article-title":"Production and characterization of a PEGylated derivative of recombinant human deoxyribonuclease I for cystic fibrosis therapy","volume":"524","author":"Guichard","year":"2017","journal-title":"Int. J. Pharm."},{"key":"2021113010583852600_B17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug. Discov. Today"},{"key":"2021113010583852600_B18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1165\/rcmb.4866","article-title":"Polyethylene glycol conjugation at Cys 232 prolongs the half-life of \u03b1 1 proteinase inhibitor","volume":"27","author":"Cantin","year":"2002","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2021113010583852600_B19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2014.05.021","article-title":"PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract","volume":"187","author":"Koussoroplis","year":"2014","journal-title":"J. Control Release Elsevier B.V."},{"key":"2021113010583852600_B20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijpharm.2017.02.021","article-title":"PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab\u2019 antibody fragment after pulmonary delivery in three different species","volume":"521","author":"Freches","year":"2017","journal-title":"Int. J. Pharm."},{"key":"2021113010583852600_B21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3111\/13696998.2013.787427","article-title":"Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis","volume":"16","author":"Nasr","year":"2013","journal-title":"J. Med. Econ."},{"key":"2021113010583852600_B22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0169-409X(02)00027-3","article-title":"Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications","volume":"54","author":"Wang","year":"2002","journal-title":"Adv. Drug. Deliv. Rev. Elsevier"},{"key":"2021113010583852600_B23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-015-0127-4","article-title":"Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor","volume":"29","author":"Arvedson","year":"2015","journal-title":"BioDrugs"},{"key":"2021113010583852600_B24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cocis.2017.08.001","article-title":"PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals","volume":"31","author":"Guichard","year":"2017","journal-title":"Curr Opin Colloid Interface Sci."},{"key":"2021113010583852600_B25","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1073\/pnas.71.12.4742","article-title":"Actin is the naturally occurring inhibitor of deoxyribonuclease I","volume":"71","author":"Lazarides","year":"1974","journal-title":"Proc. Natl. Acad. Sci.U.S.A."},{"key":"2021113010583852600_B26","first-page":"119","article-title":"In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis","volume":"51","author":"Shah","year":"1996","journal-title":"Thorax. BMJ Publishing Group"},{"key":"2021113010583852600_B27","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/thx.2006.060814","article-title":"Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis","volume":"61","author":"Sanders","year":"2006","journal-title":"Thorax"},{"key":"2021113010583852600_B28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/thx.33.2.235","article-title":"Pus, deoxyribonucleic acid, and sputum viscosity","volume":"33","author":"Picot","year":"1978","journal-title":"Thorax"},{"key":"2021113010583852600_B29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1203\/00006450-198102000-00007","article-title":"Is cystic fibrosis mucus abnormal?","volume":"15","author":"King","year":"1981","journal-title":"Pediatr. Res."},{"key":"2021113010583852600_B30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1465-9921-10-63","article-title":"Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum","volume":"10","author":"Serisier","year":"2009","journal-title":"Respir Res."},{"key":"2021113010583852600_B31","article-title":"Annual report Belgian cystic fibrosis registry 2015","author":"Wanyama","year":"2015"},{"key":"2021113010583852600_B32","doi-asserted-by":"publisher","first-page":"L1240","DOI":"10.1152\/ajplung.00206.2007","article-title":"Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis","volume":"293","author":"Broughton-Head","year":"2007","journal-title":"AJP Lung Cell Mol. Physiol."},{"key":"2021113010583852600_B33","article-title":"Quant-iTTM PicoGreen \u00ae dsDNA Reagent and Kits","author":"Invitrogen","year":"2008"},{"key":"2021113010583852600_B34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.pupt.2006.08.008","article-title":"Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics","volume":"20","author":"Broughton-Head","year":"2007","journal-title":"Pulm. Pharmacol. Ther."},{"key":"2021113010583852600_B35","doi-asserted-by":"publisher","first-page":"e87681","DOI":"10.1371\/journal.pone.0087681","article-title":"A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease. Waigh T, editor","volume":"9","author":"Hill","year":"2014","journal-title":"PLoS One."},{"key":"2021113010583852600_B36","doi-asserted-by":"publisher","first-page":"e82297","DOI":"10.1371\/journal.pone.0082297","article-title":"A new method to improve the clinical evaluation of cystic fibrosis patients by mucus viscoelastic properties. Shukla D, editor","volume":"9","author":"Tomaiuolo","year":"2014","journal-title":"PLoS One."},{"key":"2021113010583852600_B37","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/jbm.a.34914","article-title":"Strain rate viscoelastic analysis of soft and highly hydrated biomaterials","volume":"102","author":"Tirella","year":"2014","journal-title":"J. Biomed. Mater. Res. A. Wiley-Blackwell"},{"key":"2021113010583852600_B38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3233\/BIR-1985-22505","article-title":"Elasto-thixotropic properties of bronchial mucus and polymer analogs. I. Experimental results","volume":"22","author":"Puchelle","year":"1985","journal-title":"Biorheology"},{"key":"2021113010583852600_B39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/0954-6111(95)90126-4","article-title":"Two years experience with recombinant Human DNase I in the treatment of pulmonary disease in cystic fibrosis","volume":"89","author":"Shah","year":"1995","journal-title":"Respir. Med."},{"key":"2021113010583852600_B40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bpc.2004.07.019","article-title":"Elastic contributions dominate the viscoelastic properties of sputum from cystic fibrosis patients","volume":"112","author":"Nielsen","year":"2004","journal-title":"Biophys. Chem."},{"key":"2021113010583852600_B41","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/elps.1150180704","article-title":"Analysis of the binding of deoxyribonuclease I to G-actin by capillary electrophoresis","volume":"18","author":"Carter","year":"1997","journal-title":"Electrophoresis."},{"key":"2021113010583852600_B42","first-page":"199","article-title":"Studies on pulmonary secretions. I. The over-all chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy","volume":"88","author":"Matthews","year":"1963","journal-title":"Am Rev. Respir. Dis."},{"key":"2021113010583852600_B43","first-page":"937","article-title":"A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia","volume":"337","author":"Button","year":"2012"},{"key":"2021113010583852600_B44","first-page":"281","article-title":"Pancreatic DNase.","volume-title":"The Enzymes","author":"Moore","year":"1981","edition":"3rd ed"},{"key":"2021113010583852600_B45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF01567570","article-title":"Composition of sputum from patients with cystic fibrosis","volume":"11","author":"Kilbourn","year":"1984","journal-title":"Curr. Microbiol."},{"key":"2021113010583852600_B46","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1110\/ps.8.9.1780","article-title":"Ca2+-dependent activity of human DNase I and its hyperactive variants","volume":"8","author":"Pan","year":"1999","journal-title":"Protein Sci."},{"key":"2021113010583852600_B47","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/oxfordjournals.jbchem.a134875","article-title":"Effects of KCl, MgCl2, and CaCl2 concentrations on the monomer-polymer equilibrium of actin in the presence and absence of cytochalasin D","volume":"96","author":"Maruyama","year":"1984","journal-title":"J. Biochem."},{"key":"2021113010583852600_B48","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.1021\/bi300873f","article-title":"The structure of human DNase I bound to magnesium and phosphate ions points to a catalytic mechanism common to members of the DNase I-like superfamily","volume":"51","author":"Parsiegla","year":"2012","journal-title":"Biochemistry"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/132\/13\/1439\/449508\/cs-2018-0315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/132\/13\/1439\/449508\/cs-2018-0315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:50:48Z","timestamp":1638273048000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/132\/13\/1439\/72001\/Impact-of-PEGylation-on-the-mucolytic-activity-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":48,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,7,18]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20180315","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]}}}